BRPI0407300A - Usos de um inibidor funcional da proteìna hsgk1 ou da proteìna hsgk3 ou de um regulador negativo da transcrição do gene hsgk1 ou do gene hsgk3, de um ácido nucleico de filamento único ou filamento duplo e de um anticorpo, fármaco, kit para diagnóstico, e, método de triagem para identificar e caracterizar substâncias terapeuticamente ativas - Google Patents

Usos de um inibidor funcional da proteìna hsgk1 ou da proteìna hsgk3 ou de um regulador negativo da transcrição do gene hsgk1 ou do gene hsgk3, de um ácido nucleico de filamento único ou filamento duplo e de um anticorpo, fármaco, kit para diagnóstico, e, método de triagem para identificar e caracterizar substâncias terapeuticamente ativas

Info

Publication number
BRPI0407300A
BRPI0407300A BR0407300-2A BRPI0407300A BRPI0407300A BR PI0407300 A BRPI0407300 A BR PI0407300A BR PI0407300 A BRPI0407300 A BR PI0407300A BR PI0407300 A BRPI0407300 A BR PI0407300A
Authority
BR
Brazil
Prior art keywords
hsgk1
hsgk3
gene
protein
nucleic acid
Prior art date
Application number
BR0407300-2A
Other languages
English (en)
Inventor
Florian Lang
Original Assignee
Florian Lang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florian Lang filed Critical Florian Lang
Publication of BRPI0407300A publication Critical patent/BRPI0407300A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/166—Cataract
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"USOS DE UM INIBIDOR FUNCIONAL DA PROTEìNA HSGK1 OU DA PROTEìNA HSGK3 OU DE UM REGULADOR NEGATIVO DA TRANSCRIçãO DO GENE HSGK1 OU DO GENE HSGK3, DE UM áCIDO NUCLEICO DE FILAMENTO úNICO OU FILAMENTO DUPLO E DE UM ANTICORPO, FáRMACO, KIT PARA DIAGNóSTICO, E, MéTODO DE TRIAGEM PARA IDENTIFICAR E CARACTERIZAR SUBSTâNCIAS TERAPEUTICAMENTE ATIVAS". A invenção refere-se ao uso de um inibidor funcional de proteína hsgk1 ou hsgk3 ou um regulador de transcrição negativo de gene hsgk1 ou hsgk3 na produção de um medicamento para o tratamento e/ou profilaxia de uma catarata, glaucoma ou neuropatia diabética. Outro aspecto da invenção refere-se ao uso de um ácido nucleico de filamento único ou filamento duplo compreendendo a seq³ência hsgk1 de acordo com número de acesso NM005627 ou um dos fragmentos dos mesmos ou compreendendo a seq³ência hsgk3 de acordo com número de acesso AFI69035 ou um dos fragmentos dos mesmos no diagnóstico de uma predisposição à formação de uma catarata, glaucoma e/ou neuropatia diabética, além de um kit para diagnóstico de uma predisposição à formação de uma catarata, glaucoma e/ou neuropatia diabética, compreendendo o ácido nucleico acima mencionado. A invenção ainda refere-se a vários métodos de triagem para a identificação e caracterização de substâncias terapeuticamente eficazes dentre uma pluralidade de substâncias de teste para o tratamento e/ou profilaxia de, pelo menos, uma doença selecionada dentre catarata, glaucoma ou neuropatia diabética.
BR0407300-2A 2003-02-07 2004-02-05 Usos de um inibidor funcional da proteìna hsgk1 ou da proteìna hsgk3 ou de um regulador negativo da transcrição do gene hsgk1 ou do gene hsgk3, de um ácido nucleico de filamento único ou filamento duplo e de um anticorpo, fármaco, kit para diagnóstico, e, método de triagem para identificar e caracterizar substâncias terapeuticamente ativas BRPI0407300A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10305212A DE10305212A1 (de) 2003-02-07 2003-02-07 Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
PCT/EP2004/001048 WO2004069258A2 (de) 2003-02-07 2004-02-05 Verwendung der sgk-genfamilie zur diagnose und zur therapie von katarakt und glaukom

Publications (1)

Publication Number Publication Date
BRPI0407300A true BRPI0407300A (pt) 2006-02-07

Family

ID=32730900

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407300-2A BRPI0407300A (pt) 2003-02-07 2004-02-05 Usos de um inibidor funcional da proteìna hsgk1 ou da proteìna hsgk3 ou de um regulador negativo da transcrição do gene hsgk1 ou do gene hsgk3, de um ácido nucleico de filamento único ou filamento duplo e de um anticorpo, fármaco, kit para diagnóstico, e, método de triagem para identificar e caracterizar substâncias terapeuticamente ativas

Country Status (13)

Country Link
EP (1) EP1663246A2 (pt)
JP (1) JP2006519189A (pt)
KR (1) KR20050114214A (pt)
CN (1) CN1771039A (pt)
AU (1) AU2004210416A1 (pt)
BR (1) BRPI0407300A (pt)
CA (1) CA2514703A1 (pt)
DE (1) DE10305212A1 (pt)
MX (1) MXPA05008394A (pt)
PL (1) PL378399A1 (pt)
RU (1) RU2005127808A (pt)
WO (1) WO2004069258A2 (pt)
ZA (1) ZA200506280B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006135653A (ru) * 2004-03-11 2008-04-20 Мерк Патент ГмбХ (DE) Способы, препятствующие фиброзу
KR20070015148A (ko) * 2004-03-11 2007-02-01 메르크 파텐트 게엠베하 혈청 및 글루코코르티코이드 유도가능한 키나아제의조절제의 용도를 포함하는 신경정신학적 장애를 치료하기위한 글루탐산 수용체의 조절 방법
DE102004059781A1 (de) * 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Verwendung der Serum-/Glucocorticoid regulierten Kinase
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
WO2007037560A1 (ja) * 2005-09-30 2007-04-05 Link Genomics, Inc. Ｓｇｋ２遺伝子の治療的又は診断的用途
CA2630668C (en) * 2005-11-22 2016-07-12 Mcgill University Intraocular pressure-regulated early genes and uses thereof
WO2008079980A1 (en) * 2006-12-22 2008-07-03 Alcon Research, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma
DE102008029072A1 (de) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen
BR112013018374A2 (pt) * 2011-01-25 2016-10-11 Monell Chemical Senses Centre composições e métodos para fornecer ou modular o sabor doce e métodos para rastrear os mesmos
KR102357260B1 (ko) * 2020-12-10 2022-02-08 주식회사 레피겐엠디 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트
CN119303113A (zh) * 2024-09-03 2025-01-14 河北大学附属医院 Nedd4l基因在制备治疗血管内皮细胞增生性相关疾病药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535673D1 (de) * 1994-08-30 2008-02-07 Univ Dundee Mittel zur induktion von apoptosis und zur therapieanwendung
WO1996041013A1 (en) * 1995-06-07 1996-12-19 Ligand Pharmaceuticals Incorporated Method for screening for receptor agonists and antagonists
US5925523A (en) * 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
DE19708173A1 (de) * 1997-02-28 1998-09-03 Dade Behring Marburg Gmbh Zellvolumenregulierte humane Kinase h-sgk
WO1999059559A1 (en) * 1998-05-15 1999-11-25 Joslin Diabetes Center Independent regulation of basal and insulin-stimulated glucose transport
ATE373676T1 (de) * 1998-12-14 2007-10-15 Univ Dundee Verfahren zur aktivierung von sgk durch phosphorylierung.
US6399655B1 (en) * 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
AU5840300A (en) * 1999-07-14 2001-01-30 University Of Lausanne Glutx polypeptide family and nucleic acids encoding same
US6416759B1 (en) * 1999-09-30 2002-07-09 The Regents Of The University Of California Antiproliferative Sgk reagents and methods
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10225844A1 (de) * 2002-06-04 2003-12-18 Lang Florian sgk und nedd als diagnostische und therapeutische targets

Also Published As

Publication number Publication date
JP2006519189A (ja) 2006-08-24
CN1771039A (zh) 2006-05-10
EP1663246A2 (de) 2006-06-07
ZA200506280B (en) 2006-05-31
CA2514703A1 (en) 2004-08-19
AU2004210416A1 (en) 2004-08-19
WO2004069258A2 (de) 2004-08-19
MXPA05008394A (es) 2005-10-05
PL378399A1 (pl) 2006-04-03
KR20050114214A (ko) 2005-12-05
DE10305212A1 (de) 2004-08-19
RU2005127808A (ru) 2006-05-27
WO2004069258A3 (de) 2005-02-24

Similar Documents

Publication Publication Date Title
Tanaka et al. Profiles of extracellular miRNAs in the aqueous humor of glaucoma patients assessed with a microarray system
Garweg et al. Comparison of cytokine profiles in the aqueous humor of eyes with pseudoexfoliation syndrome and glaucoma
Mörtberg et al. S-100B is superior to NSE, BDNF and GFAP in predicting outcome of resuscitation from cardiac arrest with hypothermia treatment
EP2558862B1 (en) Diagnostic methods for glaucoma
Loeffler et al. Collagen VIII influences epithelial phenotypic changes in experimental diabetic nephropathy
WO2017106363A1 (en) Refining diagnosis and treatment of complex multi-symptom neurological disorders
Jünemann et al. Elevated vitreous body glial fibrillary acidic protein in retinal diseases
BRPI0407300A (pt) Usos de um inibidor funcional da proteìna hsgk1 ou da proteìna hsgk3 ou de um regulador negativo da transcrição do gene hsgk1 ou do gene hsgk3, de um ácido nucleico de filamento único ou filamento duplo e de um anticorpo, fármaco, kit para diagnóstico, e, método de triagem para identificar e caracterizar substâncias terapeuticamente ativas
Lynch et al. Plasma biomarkers of reticular pseudodrusen and the risk of progression to advanced age-related macular degeneration
Rasmussen et al. Impulsivity in hoarding
Ersin Kalkan et al. Salivary fetuin‐A, S100A12, and high‐sensitivity C‐reactive protein levels in periodontal diseases
Garweg et al. Cytokine profiles of phakic and pseudophakic eyes with primary retinal detachment
Chandran et al. Vitreous from idiopathic epiretinal membrane patients induces glial-to-mesenchymal transition in Müller cells
Gijs et al. Tear fluid inflammatory proteome analysis highlights similarities between keratoconus and allergic conjunctivitis
Khawaja et al. Potential for collider bias in studies examining the association of central corneal thickness with glaucoma
CN120129834A (zh) 用于评估和治疗神经退行性疾病的蛋白质标志物
Gerace et al. The gliadin peptide 31-43 exacerbates kainate neurotoxicity in epilepsy models
EP3918336A1 (en) Prospective markers in traumatic brain injury (tbi)
Steuer et al. Using the olfactory system as an in vivo model to study traumatic brain injury and repair
US20150301049A1 (en) Method for diagnosing and treating kidney injury or disease
CN113009158B (zh) 中高度近视的辅助诊断标记物及其用途
KR102411177B1 (ko) Chrna3를 포함하는 난청 진단용 바이오마커 조성물 및 이의 용도
SE0002189D0 (sv) New method and assay
Bharwani et al. Serum Soluble Interleukin‐2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting
WO2017175181A1 (en) Angiogenin as a diagnostic or prognostic biomarker and drug target in age-related macular degeneration

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.